Anna Kuzevanova

Ms. Anna Kuzevanova

Research Centre for Medical Genetics, Moscow, Moskva, Russia
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2021 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
AKAlexandra Korotaeva
Alexandra Korotaeva
DMDanzan Mansorunov
Danzan Mansorunov
NANatalya Apanovich
Natalya Apanovich
AKAnna Kuzevanova
Anna Kuzevanova
AKAlexander Karpukhin
Alexander Karpukhin
Neuroendocrine neoplasms (NEN) are infrequent malignant tumors of a neuroendocrine nature that arise in various organs. They occur most frequently in the lungs, intestines, stomach and pancreas. Molecular diagnostics and prognosis of NEN development are highly relevant. The role of clinical biomarkers can be played by microRNAs (miRNAs). This work is devoted to the analysis of data on miRNA expression in NENs. For the first time, a search for specificity or a community of their functional characteristics in different types of NEN was carried out. Their properties as biomarkers were also analyzed. To date, more than 100 miRNAs have been characterized as differentially expressed and significant for the development of NEN tumors. Only about 10% of the studied miRNAs are expressed in several types of NEN; differential expression of the remaining 90% was found only in tumors of specific localizations. A significant number of miRNAs have been identified as potential biomarkers. However, only a few miRNAs have values that characterized their quality as markers. The analysis demonstrates the predominant specific expression of miRNA in each studied type of NEN. This indicates that miRNA’s functional features are predominantly influenced by the tissue in which they are formed.

25 August 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
AKAnna Kuzevanova
Anna Kuzevanova
NANatalya Apanovich
Natalya Apanovich
DMDanzan Mansorunov
Danzan Mansorunov
AKAlexandra Korotaeva
Alexandra Korotaeva
AKAlexander Karpukhin
Alexander Karpukhin
To date, certain problems have been identified in cancer immunotherapy using the inhibition of immune checkpoints (ICs). Despite the excellent effect of cancer therapy in some cases when blocking the PD-L1 (programmed death-ligand 1) ligand and the immune cell receptors PD-1 (programmed cell death protein 1) and CTLA4 (cytotoxic T-lymphocyte-associated protein 4) with antibodies, the proportion of patients responding to such therapy is still far from desirable. This situation has stimulated the exploration of additional receptors and ligands as targets for immunotherapy. In our article, based on the analysis of the available data, the TIM-3 (T-cell immunoglobulin and mucin domain-3), LAG-3 (lymphocyte-activation gene 3), TIGIT (T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains), VISTA (V-domain Ig suppressor of T-cell activation), and BTLA (B- and T-lymphocyte attenuator) receptors and their ligands are comprehensively considered. Data on the relationship between receptor expression and the clinical characteristics of tumors are presented and are analyzed together with the results of preclinical and clinical studies on the therapeutic efficacy of their blocking. Such a comprehensive analysis makes it possible to assess the prospects of receptors of this series as targets for anticancer therapy. The expression of the LAG-3 receptor shows the most unambiguous relationship with the clinical characteristics of cancer. Its inhibition is the most effective of the analyzed series in terms of the antitumor response. The expression of TIGIT and BTLA correlates well with clinical characteristics and demonstrates antitumor efficacy in preclinical and clinical studies, which indicates their high promise as targets for anticancer therapy. At the same time, the relationship of VISTA and TIM-3 expression with the clinical characteristics of the tumor is contradictory, and the results on the antitumor effectiveness of their inhibition are inconsistent.

16 December 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
DMDanzan Mansorunov
Danzan Mansorunov
NANatalya Apanovich
Natalya Apanovich
PAPavel Apanovich
Pavel Apanovich
FKFatimat Kipkeeva
Fatimat Kipkeeva
TMTatyana A. Muzaffarova
Tatyana A. Muzaffarova
AKAlexander Karpukhin
Alexander Karpukhin
To increase the effectiveness of anticancer therapy based on immune checkpoint (IC) inhibition, some ICs are being investigated in addition to those used in clinic. We reviewed data on the relationship between PD-L1, B7-H3, B7-H4, IDO1, Galectin-3 and -9, CEACAM1, CD155, Siglec-15 and ADAM17 expression with cancer development in complex with the results of clinical trials on their inhibition. Increased expression of the most studied ICs—PD-L1, B7-H3, and B7-H4—is associated with poor survival; their inhibition is clinically significant. Expression of IDO1, CD155, and ADAM17 is also associated with poor survival, including gastric cancer (GC). The available data indicate that CD155 and ADAM17 are promising targets for immune therapy. However, the clinical trials of anti-IDO1 antibodies have been unsatisfactory. Expression of Galectin-3 and -9, CEACAM1 and Siglec-15 demonstrates a contradictory relationship with patient survival. The lack of satisfactory results of these IC inhibitor clinical trials additionally indicates the complex nature of their functioning. In conclusion, in many cases it is important to analyze the expression of other participants of the immune response besides target IC. The PD-L1, B7-H3, B7-H4, IDO1 and ADAM17 may be considered as candidates for prognosis markers for GC patient survival.

30 November 2019 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
DMDanzan Mansorunov
Danzan Mansorunov
AAAndrei Alimov
Andrei Alimov
NAN. V. Apanovich
N. V. Apanovich
AKAnna Kuzevanova
Anna Kuzevanova
TBTatiana Bogush
Tatiana Bogush
AKAlexander Karpukhin
Alexander Karpukhin
Gastric cancer (GC) takes 5th place among the malignant neoplasms by incidence in the world. Mortality from GC is high, since in most cases the disease is diagnosed in the late stages, with distant metastases, the five-year survival in GC does not exceed 25–30 %. The standard for GC therapy is surgery with chemotherapy. There is a high resistance to chemotherapy in the late stages of GC, and this circumstance requires a fundamentally new therapy. Recently, studies have been actively conducted on the therapy of GC with the immune control point inhibitors. At the moment, the most studied are monoclonal antibodies against PD-1 (Programmed cell death 1, CD279) / PDL1 (Programmed death-ligand 1, CD274), CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4, CD152). The article discusses the characteristics of PD-1, PD-L1, CTLA-4 molecules and their significance in suppressing the T-cell response, as well as the antitumor effect of immune control point inhibitors. The results of clinical studies of GC therapy with monoclonal antibodies against PD-1 / PD-L1, CTLA-4 were analyzed. The immune control point inhibitors are used as both first-line therapy and subsequent ones. The negative side of immunotherapy is immune-mediated adverse events that can affect the tissues of the kidneys, heart, gastrointestinal tract, liver, lungs, skin and endocrine glands. Biomarkers of the effectiveness of the immune control point inhibitors for GC are considered, among which one can distinguish PD-L1 expression, microsatellite instability, gene expression profile, tumor mutational load and composition of the intestinal microbiome.

23 April 2023 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
AKAlexandra Korotaeva
Alexandra Korotaeva
ABA.A. Borunova
A.A. Borunova
AKAnna Kuzevanova
Anna Kuzevanova
TZT.N. Zabotina
T.N. Zabotina
AAAndrei Alimov
Andrei Alimov
The review summarizes data on the features of antigen presentation in tumor cells. The molecular mechanisms of the antitumor immune response are considered with an emphasis on the ability of tumor cells to avoid the action of immune surveillance. The features of expression of MHC molecules depending on treatment regimens are provided. Ways to improve existing and create new treatment regimens aimed at elimination of tumor cells because of antitumor immune response are discussed.

1 April 2022 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
NANatalya Apanovich
Natalya Apanovich
PAP. V. Apanovich
P. V. Apanovich
DMDanzan Mansorunov
Danzan Mansorunov
AKAnna Kuzevanova
Anna Kuzevanova
AKAlexandra Korotaeva
Alexandra Korotaeva
AKAlexander Karpukhin
Alexander Karpukhin